Evidence for Rho-kinase activation in patients with pulmonary arterial hypertension

Circulation Journal

Volumn 73, Issue 9, 2009, Pages 1731-1739

  Do e, Zhulanqiqige ^a   Fukumoto, Yoshihiro ^a   Takaki, Aya ^a   Tawara, Shunsuke ^a   Ohashi, Junko ^a   Nakano, Makoto ^a   Tada, Tomohiro ^a   Saji, Kenya ^a   Sugimura, Kohichiro ^a   Fujita, Hiroshi ^a   Hoshikawa, Yasushi ^a   Nawata, Jun ^a   Kondo, Takashi ^a   Shimokawa, Hiroaki ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Endothelial function; Pulmonary hypertension; Rho kinase; Signal transduction; Vascular smooth muscle

Indexed keywords

HYDROXYFASUDIL; MYOSIN BINDING SUBUNIT; MYOSIN SUBFRAGMENT; RHO KINASE; SEROTONIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD VESSEL REACTIVITY; CLINICAL ARTICLE; CONGENITAL HEART DISEASE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; ENDOTHELIUM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN TISSUE; IDIOPATHIC DISEASE; IN VITRO STUDY; ISOLATED LUNG; LUNG PARENCHYMA; MALE; MUSCLE CONTRACTION; MUSCLE RELAXATION; NEUTROPHIL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; PULMONARY ARTERY; PULMONARY HYPERTENSION; THROMBOEMBOLISM;

ADULT; CASE-CONTROL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; FEMALE; HUMANS; HYPERTENSION, PULMONARY; LUNG; MALE; MIDDLE AGED; MYOSIN-LIGHT-CHAIN PHOSPHATASE; NEUTROPHILS; PHOSPHORYLATION; PROSPECTIVE STUDIES; PROTEIN KINASE C-ALPHA; PROTEIN KINASE C-DELTA; PROTEIN KINASE INHIBITORS; PULMONARY ARTERY; RHO-ASSOCIATED KINASES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS; VASODILATION; VASODILATOR AGENTS;

EID: 69549129206     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-09-0135     Document Type: Article

References (51)

1. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351: 1425-1436. (Pubitemid 39302645)
2. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: 13S-24S. (Pubitemid 38759713)
3. McLaughlin VV, McGoon MD. Pulmonary arterial hypertension. Circulation 2006; 114: 1417-1431.
4. Fukumoto Y, Tawara S, Shimokawa H. Recent progress in the treatment of pulmonary arterial hypertension: Expectation for Rho-kinase inhibitors. Tohoku J Exp Med 2007; 211: 309-320. (Pubitemid 46585544)
5. Ishizaki T, Maekawa M, Fujisawa K, Okawa K, Iwamatsu A, Fujita A, et al. The small GTP-binding protein Rho binds to and activates a 160 kDa Ser/Thr protein kinase homologous to myotonic dystrophy kinase. EMBO J 1996; 15: 1885-1893. (Pubitemid 26119224)
6. Amano M, Chihara K, Kimura K, Fukata Y, Nakamura N, Matsuura Y, et al. Formation of actin stress fibers and focal adhesions enhanced by Rho-kinase. Science 1997; 275: 1308-1311. (Pubitemid 27114159)
7. Narumiya S. The small GTPase Rho: Cellular functions and signal transduction. J Biochem 1996; 120: 215-228. (Pubitemid 26335910)
8. Loirand G, Guerin P, Pacaud P. Rho kinases in cardiovascular physiology and pathophysiology. Circ Res 2006; 98: 322-334. (Pubitemid 43755328)
9. Shimokawa H, Takeshita A. Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol 2005; 25: 1767-1775. (Pubitemid 41243442)
10. Abe K, Shimokawa H, Morikawa K, Uwatoku T, Oi K, Matsumoto Y, et al. Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ Res 2004; 94: 385-393. (Pubitemid 38240731)
11. Abe K, Tawara S, Oi K, Hizume T, Uwatoku T, Fukumoto Y, et al. Long-term inhibition of Rho-kinase ameliorates hypoxia-induced pulmonary hypertension in mice. J Cardiovasc Pharmacol 2006; 48: 280-285. (Pubitemid 46066832)
12. Oka M, Homma N, McMurtry IF. Rho kinase-mediated vasoconstriction on rat models of pulmonary hypertension. Methods Enzymol 2008; 439: 191-204.
13. Oka M, Fagan KA, Jones PL, McMurtry IF. Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension. Br J Pharmacol 2008; 155: 444-454.
14. Fukumoto Y, Matoba T, Ito A Tanaka H, Kishi T, Hayashidani S, et al. Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart 2005; 91: 391-392. (Pubitemid 40299237)
15. Ishikura K, Yamada N, Ito M, Ota S, Nakamura M, Isaka N, et al. Beneficial acute effects of Rho-kinase inhibitor in patients with pulmonary arterial hypertension. Circ J 2006; 70: 174-178. (Pubitemid 43170128)
16. Rashid M, Tawara S, Fukumoto Y, Seto M, Yano K, Shimokawa H. Importance of Rac1 signaling pathway inhibition in the pleiotropic effect of HMG-CoA reductase inhibitors. Circ J 2009; 73: 361-370.
17. Liu PY, Chen JH, Lin LJ, Liao JK. Increased Rho kinase activity in a Taiwanese population with metabolic syndrome. J Am Coll Cardiol 2007; 49: 1619-1624. (Pubitemid 46551629)
18. Eto M, Kitazawa T, Yazawa M, Mukai H, Ono Y, Brautigan DL. Histamine-induced vasoconstriction involves phosphorylation of a spedific inhibitor protein for myosin phosphotase by protein kinase C α and δ isoforms. J Biol Chem 2001; 276: 29072-29078. (Pubitemid 37451994)
19. Zemilikova E, Johannes FJ, Aitken A, Dubois T. Association of CPI-17 with protein kinase C and casein kinase I. Biochem Biophys Res Commun 2004; 316: 39-47. (Pubitemid 38299125)
20. Noma K, Rikitake Y, Oyama M, Yan G, Alcaide P, Liu PY, et al. ROCK1 mediates leukocyte recruitment and neointima formation following vascular injury. J Clin Invest 2008; 118: 1632-1644. (Pubitemid 351632368)
21. Nakano M, Satoh K, Fukumoto Y, Ito Y, Kagaya Y, Ishii N, et al. Important role of erythropoietin receptor to promote VEGF expression and angiogenesis in peripheral ischemia in mice. Circ Res 2007; 100: 662-669. (Pubitemid 46594880)
22. Fukumoto Y, Deguchi JO, Libby P, Rabkin-Aikawa E, Sakata Y, Chin MT, et al. Genetically determined resistance to collagenase action augments interstitial collagen accumulation in atherosclerotic plaques. Circulation 2004; 110: 1953-1959. (Pubitemid 39331907)
23. Tsutsui M, Shimokawa H, Tanaka S, Kuwaoka I, Hase K, Nogami N, et al. Endothelial Gi protein in human coronary arteries. Eur Heart J 1994; 15: 1261-1266. (Pubitemid 124005616)
24. Vlahos NF, Gregoriou O, Deliveliotou A, Perrea D, Vlachos A, Zhao Y, et al. Effect of pentoxifylline on vascular endothelial growth factor C and flk-1 expression on endometrial implants in the rat endometriosis model. Fertil Steril 2009; Jan 13 [E-pub ahead of print].
25. Masumoto A, Hirooka Y, Shimokawa H, Hironaga K, Setoguchi S, Takeshita A. Possible involvement of Rho-kinase in the pathogenesis of hypertension in humans. Hypertension 2001; 38: 1307-1310. (Pubitemid 34033407)
26. Shimokawa H. Rho-kinase as a novel therapeutic target in treatment of cardiovascular diseases. J Cardiovasc Pharmacol 2002; 39: 319-327. (Pubitemid 34175055)
27. Shimokawa H, Hiramori K, Iinuma H, Hosoda S, Kishida H, Osada H, et al. Anti-anginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: A multicenter study. J Cardiovasc Pharmacol 2002; 40: 751-761. (Pubitemid 36109293)
28. Kandabashi T, Shimokawa H, Miyata K, Kunihiro I, Eto Y, Morishige K, et al. Evidence for protein kinase C-mediated activation of Rho-kinase in a porcine model of coronary artery spasm. Arterioscler Thromb Vasc Biol 2003; 23: 2209-2214. (Pubitemid 37532322)
29. Mohri M, Shimokawa H, Hirakawa Y, Masumoto A, Takeshita A. Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm. J Am Coll Cardiol 2003; 41: 15-19. (Pubitemid 36044397)
30. Matsumoto Y, Uwatoku T, Oi K, Abe K, Hattori T, Morishige K, et al. Long-term inhibition of Rho-kinase suppresses neointimal formation after stent implantation in porcine coronary arteries: Involvement of multiple mechanisms. Arterioscler Thromb Vasc Biol 2004; 24: 181-186.
31. Kishi T, Hirooka Y, Masumoto A, Ito K, Kimura Y, Inokuchi K, et al. Rho-kinase inhibitor improves increased vascular resistance and impaired vasodilation of the forearm in patients with heart failure. Circulation 2005; 111: 2741-2747.
32. Fukumoto Y, Mohri M, Inokuchi K, Ito A, Hirakawa Y, Masumoto A, et al. Anti-ischemic effects of fasudil, a specific Rho-kinase inhibitor, in patients with stable effort angina. J Cardiovasc Pharmacol 2007; 49: 117-121. (Pubitemid 46579944)
33. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995; 333: 214-221.
34. Xu W, Kaneko FT, Zheng S, Comhair SA, Janocha AJ, Goggans T, et al. Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertension. FASEB J 2004; 18: 1746-1748.
35. + channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation 1998; 98: 1400-1406. (Pubitemid 28462800)
36. Takemoto M, Sun J, Hiroki J, Shimokawa H, Liao JK. Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation 2002; 106: 57-62. (Pubitemid 34747442)
37. Shimokawa H, Rashid M. Development of Rho-kinase inhibitors for cardiovascular medicine. Trends Pharmacol Sci 2007; 28: 296-302. (Pubitemid 46818464)
38. Liao JK, Seto M, Noma K. Rho kinase (ROCK) inhibitors. J Cardiovasc Pharmacol 2007; 50: 17-24.
39. Tapson VF, Humbert M. Incidence and prevalence of chronic thromboembolic pulmonary hypertension: From acute to chronic pulmonary embolism. Proc Am Thorac Soc 2006; 3: 564-567. (Pubitemid 44411620)
40. Wu DK, Hsiao S, Lin SK, Lee CY, Tang SH, Chang SM, et al. Main pulmonary arterial distensibility: Different presentation between chronic pulmonary hypertension and acute pulmonary embolism. Circ J 2008; 72: 1454-1459.
41. Nakagawa O, Fujisawa K, Ishizaki T, Saito Y, Nakao K, Narumiya S. ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice. FEBS Lett 1996; 392: 189-193. (Pubitemid 26276745)
42. Hoeper MM, Markevych I, Spiekerkoetter E, Welte T, Niedermeter J. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 2005; 26: 858-863. (Pubitemid 41632043)
43. Ghofrani HA, Hoeper MM. Drug combination treatment for pulmonary arterial hypertension. Dtsch Med Wochenschr 2006; 131: S330-S333.
44. Abe K, Morikawa K, Hizume T, Uwatoku T, Oi K, Seto M, et al. Prostacyclin does not inhibit Rho-kinase: An implication for the treatment of pulmonary hypertension. J Cardiovasc Pharmacol 2005; 45: 120-124. (Pubitemid 40170674)
45. Tawara S, Fukumoto Y, Shimokawa H. Effects of combined therapy with a Rho-kinase inhibitor and prostacyclin on monocrotaline-induced pulmonary hypertension in rats. J Cardiovasc Pharmacol 2007; 50: 195-200. (Pubitemid 47267745)
46. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Eng J Med 2002; 346: 896-903. (Pubitemid 34984638)
47. Mclaughlin VV, Sitbon O, Badesch DB, Barst RJ, Black C, Galiè N, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005; 25: 244-249. (Pubitemid 40246523)
48. Hiramoto Y, Shioyama W, Kuroda T, Masaki M, Sugiyama S, Okamoto K, et al. Effect of bosentan on plasma endothelin-1 concentration in patients with pulmonary arterial hypertension. Circ J 2007; 71: 367-368. (Pubitemid 46409540)
49. Akagi S, Matsubara H, Miyaji K, Ikeda E, Dan K, Tokunaga N, et al. Additional effects of bosentan in patients with idiopathic pulmonary arterial hypertension already treated with high-dose epoprostenol. Circ J 2008; 72: 1142-1146. (Pubitemid 351957082)
50. Hiroki J, Shimokawa H, Higashi M, Morikawa K, Kandabashi T, Kawamura N, et al. Inflammatory stimuli upregulate Rho-kinase in human coronary vascular smooth muscle cells. J Mol Cell Cardiol 2004; 37: 537-546. (Pubitemid 38953381)
51. Hiroki J, Shimokawa H, Mukai Y, Ichiki T, Takeshita A. Divergent effects of estrogen and nicotine on Rho-kinase expression in human coronary vascular smooth muscle cells. Biochem Biophys Res Commun 2005; 326: 154-159. (Pubitemid 39573213)